Roche Holding AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public

Established: 1896-01-15

Employees: 103.6K

Market Cap: $270.5B

Website: http://www.roche.com

Introduction: Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.

Clinical Trials

A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Balovaptan in Children With Autism Spectrum Disorder

Phase 1

Terminated

Conditions: Autism Spectrum Disorder

Interventions: Drug: Balovaptan

First Posted Date: 2019-08-08

Last Posted Date: 2020-10-14

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 2

Registration Number: NCT04049578

Locations: 🇺🇸
Red Oak Psychiatry Associates, PA, Houston, Texas, United States
🇺🇸
Richmond Behavioral Associates, Staten Island, New York, United States
🇺🇸
University Hospitals Cleveland Medical Center; Division of Child and Adolescent Psychiatry, Cleveland, Ohio, United States

and more 2 locations

A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis

Phase 3

Active, not recruiting

Conditions: Multiple Sclerosis, Primary Progressive

Interventions: Drug: Placebo
Drug: Ocrelizumab

First Posted Date: 2019-07-29

Last Posted Date: 2025-05-31

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 1000

Registration Number: NCT04035005

Locations: 🇳🇿
Dunedin Hospital, Dunedin, New Zealand
🇺🇦
University hospital of Dnipro State Medical University, Dnipro, Ukraine
🇺🇦
Private Enterprise Clinic Medicom, Kyiv, Ukraine

and more 157 locations

Untreated FolliculaR Lymphoma Treated With OBinituzumAb in a Non-interventional Study (URBAN)

Completed

Conditions: Follicular Lymphoma

Interventions: Drug: Obinutuzumab

First Posted Date: 2019-07-26

Last Posted Date: 2025-05-09

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 299

Registration Number: NCT04034056

Locations: 🇮🇹
Ospedale Civile Dello Spirito Santo, Pescara, Abruzzo, Italy
🇮🇹
Azienda Ospedaliera Bianchi-Melacrino-Morelli, Reggio Calabria, Calabria, Italy
🇮🇹
Azienda Ospedaliera S.G. Moscati, Avellino, Campania, Italy

and more 43 locations

A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors

Phase 1

Terminated

Conditions: Acute Lymphoblastic Leukemia (ALL)
Acute Myeloid Leukemia (AML)
Solid Tumors
Neuroblastoma

Interventions: Drug: Idasanutlin
Drug: Fludarabine
Drug: Venetoclax
Drug: Cyclophosphamide
Drug: Topotecan
Drug: Cytarabine
Drug: Intrathecal Chemotherapy

First Posted Date: 2019-07-23

Last Posted Date: 2024-12-20

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 38

Registration Number: NCT04029688

Locations: 🇺🇸
Arkansas Children's Hospital Research Institute, Little Rock, Arkansas, United States
🇺🇸
Lucile Packard Children's Hospital at Stanford University; Thoracic Oncology, Palo Alto, California, United States
🇺🇸
Arnold Palmer Hosp-Children, Orlando, Florida, United States

and more 11 locations

A Study of Atezolizumab in Combination With Carboplatin Plus Etoposide to Investigate Safety and Efficacy in Patients With Untreated Extensive-Stage Small Cell Lung Cancer

Phase 3

Completed

Conditions: Small Cell Lung Carcinoma

Interventions: Drug: Atezolizumab
Drug: Carboplatin
Drug: Etoposide

First Posted Date: 2019-07-22

Last Posted Date: 2024-07-16

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 155

Registration Number: NCT04028050

Locations: 🇮🇹
Azienda Ospedaliera San Camillo Forlanini, Roma, Lazio, Italy
🇮🇹
Policlinico Universitario Agostino Gemelli, Roma, Lazio, Italy
🇮🇹
Ospedali Riuniti Di Ancona; Oncology, Ancona, Marche, Italy

and more 22 locations

A Single Ascending Dose Study to Investigate the Safety, Tolerability, Immunogenicity and Pharmacokinetics of Intravenously Administered RO7126209 in Healthy Participants

Phase 1

Completed

Conditions: Alzheimers Disease

Interventions: Drug: RO7126209
Drug: Placebo

First Posted Date: 2019-07-18

Last Posted Date: 2021-08-09

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 36

Registration Number: NCT04023994

Locations: 🇺🇸
PRA Health Sciences, Raleigh, North Carolina, United States

A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer

Phase 3

Active, not recruiting

Conditions: HER2-positive Early Breast Cancer

Interventions: Drug: Pertuzumab IV
Drug: Pertuzumab and Trastuzumab FDC SC
Drug: Trastuzumab IV
Drug: Doxorubicin
Drug: Cyclophosphamide
Drug: Docetaxel
Procedure: Surgery
Radiation: Post-Operative Radiotherapy
Drug: Hormone Therapy

First Posted Date: 2019-07-18

Last Posted Date: 2025-05-25

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 200

Registration Number: NCT04024462

Locations: 🇨🇳
Jilin Cancer Hospital, Changchun, China
🇨🇳
West China Hospital, Sichuan University, Chengdu, China
🇨🇳
The 900th Hospital of PLA joint service support force, Fuzhou, China

and more 15 locations

A Study to Investigate the Pharmacokinetics and Pharmacodynamics of RO7234292 (RG6042) in CSF and Plasma, and Safety and Tolerability Following Intrathecal Administration in Patients With Huntington's Disease

Phase 1

Completed

Conditions: Huntingtons Disease

Interventions: Drug: RO7234292 (RG6042)

First Posted Date: 2019-06-27

Last Posted Date: 2024-10-03

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 12

Registration Number: NCT04000594

Locations: 🇳🇱
Centre For Human Drug Research; Research, Leiden, Netherlands
🇬🇧
Leonard Wolfson Experimental Neurology Centre, London, United Kingdom
🇬🇧
Manchester University NHS Foundation Trust (MFT), Manchester, United Kingdom

A Drug-drug Interaction Study With Risdiplam Multiple Dose and Midazolam in Healthy Participants

Phase 1

Completed

Conditions: Spinal Muscular Atrophy

Interventions: Drug: Risdiplam
Drug: Midazolam

First Posted Date: 2019-06-18

Last Posted Date: 2020-10-19

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 35

Registration Number: NCT03988907

Locations: 🇺🇸
Covance Research Unit - Dallas, Dallas, Texas, United States

Tau Positron Emission Tomography (PET) Longitudinal Substudy Associated With: Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers in the Treatment of Autosomal-Dominant Alzheimer's Disease

Phase 2

Completed

Conditions: Alzheimer Disease

Interventions: Drug: Placebo
Drug: Crenezumab
Other: [^18F]GTP1

First Posted Date: 2019-06-06

Last Posted Date: 2024-03-15

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 114

Registration Number: NCT03977584

Locations: 🇨🇴
Grupo Neurociencias de Antioquia, Medellin, Colombia

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy